David P. Kerstein, M.D.

Dr. Kerstein most recently served as chief medical officer of IDRx, a clinical-stage precision oncology company, before its acquisition by GSK in 2025. Prior to joining IDRx, Dr. Kerstein was chief medical officer of Theseus Pharmaceuticals, Inc. Before Theseus, Dr. Kerstein was chief medical officer of Anchiano Therapeutics Ltd. Prior to these roles, Dr. Kerstein served as senior medical director in oncology clinical research and lung cancer clinical portfolio strategy lead at Takeda Pharmaceutical Company Limited and senior medical director of clinical research at ARIAD Pharmaceuticals, Inc. (acquired by Takeda in 2017) where he led the clinical development of ALUNBRIG®. Earlier in his career, Dr. Kerstein served as director of clinical development and regulatory affairs at Boston Biomedical, Inc., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co. Ltd.

Dr. Kerstein holds an M.D. from Tufts University School of Medicine and received a B.S. in Biology from Tufts University.